A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
about
Adjunctive atypical antipsychotic treatment for major depressive disorder: a meta-analysis of depression, quality of life, and safety outcomesSecond-generation antipsychotics for major depressive disorder and dysthymiaChallenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved TherapeuticsMonoaminergic and Histaminergic Strategies and Treatments in Brain DiseasesSecond Generation Antipsychotics in the Treatment of Major Depressive Disorder: An UpdateCentral serotonin-2A (5-HT2A) receptor dysfunction in depression and epilepsy: the missing link?Fluoxetine and olanzapine combination therapy in treatment-resistant major depression: review of efficacy and safety data.Safety and Tolerability of Adjunctive Aripiprazole in Major Depressive Disorder: A Pooled Post Hoc Analysis (studies CN138-139 and CN138-163).Pharmacologic approaches to treatment resistant depression: a re-examination for the modern era.The incidence of tardive dyskinesia in the study of pharmacotherapy for psychotic depression.Treatment-resistant depression in primary care across CanadaMeta-analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorderLong-term safety and tolerability of open-label aripiprazole augmentation of antidepressant therapy in major depressive disorder.Augmentation with atypical antipsychotics for depression: a review of evidence-based support from the medical literature.A review of current evidence for vilazodone in major depressive disorder.Efficacy and safety of olanzapine/fluoxetine combination vs fluoxetine monotherapy following successful combination therapy of treatment-resistant major depressive disorder.Sleep architecture and cognitive changes in olanzapine-treated patients with depression: a double blind randomized placebo controlled trial.Evidence-based guidelines for treating depressive disorders with antidepressants: a revision of the 2000 British Association for Psychopharmacology guidelines.Efficacy of adjunctive aripiprazole in patients with major depressive disorder whose symptoms worsened with antidepressant monotherapy.Pharmacologic approaches to treatment resistant depression: Evidences and personal experience.Comparative efficacy and tolerability of pharmacological and somatic interventions in adult patients with treatment-resistant depression: a systematic review and network meta-analysis.Number needed to treat to harm for discontinuation due to adverse events in the treatment of bipolar depression, major depressive disorder, and generalized anxiety disorder with atypical antipsychotics.Atypical Antipsychotic Augmentation for Treatment-Resistant Depression: A Systematic Review and Network Meta-Analysis.Contemporary concepts in the pharmacotherapy of depression in older people.Differential regulation of central BDNF protein levels by antidepressant and non-antidepressant drug treatments.Combined treatments for major depression.A randomized, placebo-controlled trial of risperidone augmentation for patients with difficult-to-treat unipolar, non-psychotic major depressionExamining the efficacy of adjunctive aripiprazole in major depressive disorder: a pooled analysis of 2 studies.A review of quetiapine in combination with antidepressant therapy in patients with depression.Olanzapine and fluoxetine combination therapy for treatment-resistant depression: review of efficacy, safety, and study design issues.Olanzapine/fluoxetine combination for treatment-resistant depression: efficacy and clinical utility.Current evidence for aripiprazole as augmentation therapy in major depressive disorder.Efficacy and safety of olanzapine/fluoxetine combination in the treatment of treatment-resistant depression: a meta-analysis of randomized controlled trials.Efficacy, safety and tolerability of Symbyax for acute-phase management of treatment-resistant depression.Adjunctive aripiprazole, olanzapine, or quetiapine for major depressive disorder: an analysis of number needed to treat, number needed to harm, and likelihood to be helped or harmed.Therapeutic options in treatment-resistant depression.Targeting treatment-resistant depression.Emerging drugs for major depressive disorder.Augmentation treatments with second-generation antipsychotics to antidepressants in treatment-resistant depression.World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for biological treatment of unipolar depressive disorders, part 1: update 2013 on the acute and continuation treatment of unipolar depressive disorders.
P2860
Q21144599-A8C544C7-CC21-440F-9CD5-1F74E8433E7CQ24235667-B3F0EE56-B302-4991-89DA-87623EB651FBQ26782997-3AE1668A-D7F9-4BE4-8A6B-B63A987EFA44Q28066691-1BE720D2-1EF6-4654-8C9C-B54CA1E2E897Q28076712-A0060FB4-4CDF-415E-83CC-FF1AF1F1F352Q28080944-D37CD1DB-C8A0-44AA-AD07-604B537705BFQ33488312-97B543CC-58AD-4FDF-A8EA-120FFBA382F9Q33587032-BEE6D1D3-227A-4A6F-8B7F-C2F6B485AE26Q33716723-3CCADA49-58EB-4E3D-A450-0E3BA5A0F946Q33770747-EBE0385B-4024-42D5-B555-A34DF6D81498Q33861601-68674ABB-44BB-4BC1-8443-5FF4BE895F65Q34010693-32713B33-85F4-46B2-92CB-63A10257E33BQ34027230-9AE74E7B-F8F4-4F33-81A8-D1F34AF3022BQ34330761-B3006E0E-FFAB-4216-A344-BD1F9C33BF71Q34338647-99107C4E-60FA-42D7-A8ED-9DAC84263F7AQ34393030-D2FC0663-593E-4A1D-B905-11DEFA882068Q34468541-3B1D65AE-AF8A-48C2-BCCA-76BC6CFB173CQ34590507-DE0F08BE-0DA1-4F4E-88F2-77E3A54A20CCQ34629315-AE313191-487C-41F5-9E9C-99697708058EQ36091234-A8892D1B-1D38-4D39-8C87-5281C39E81C6Q36236193-29AB7508-792B-4B40-9976-F7F3C950D151Q36275903-BB89A777-83F7-43A0-A8A0-2963235371B9Q36588685-A7B439B3-A560-4557-94A9-48056581E337Q36595864-60A83A31-877A-4457-BD1D-238DB2200AF3Q36672294-27E288E0-AF7A-46CC-9312-62A0ED001D39Q36916862-BA0C4676-D863-4206-B990-964D15802A2DQ36938416-FBFBBAE9-4A21-47F1-8B8C-6C76D3979D28Q37101731-56D0C861-8258-4E17-85BF-0C0D86CE645EQ37129835-58E87C97-9175-4E8A-92CE-B680E42C6AD0Q37252495-94373E0B-09E5-4B2A-A96F-F5D79FFD966DQ37256691-AF54C4D1-EA03-4418-BF03-B8778141902CQ37301196-C81FE695-4C7D-4380-B517-FB319172C3F3Q37682874-A036E93F-3319-400E-8664-B3FFEB004A90Q37737291-B203C9F8-5FF7-47FD-A331-371E69AD886FQ37777006-418D842D-517D-4A73-A9C5-BB3E67BACAEBQ37881968-6671C9E2-4363-42FB-97BC-C53428D0778AQ37957770-377B0794-A449-4285-93A2-1E33D7875652Q37984619-57399F6E-CBAE-44DE-A485-1272E76B8223Q38109589-56AE3C9A-1B39-417A-AE7F-811CF6E8065AQ38123516-4E700345-AAF7-48EA-8C56-AD458579B299
P2860
A randomized, double-blind comparison of olanzapine/fluoxetine combination, olanzapine, and fluoxetine in treatment-resistant major depressive disorder
description
2007 nî lūn-bûn
@nan
2007 թուականի Փետրուարին հրատարակուած գիտական յօդուած
@hyw
2007 թվականի փետրվարին հրատարակված գիտական հոդված
@hy
2007年の論文
@ja
2007年学术文章
@wuu
2007年学术文章
@zh-cn
2007年学术文章
@zh-hans
2007年学术文章
@zh-my
2007年学术文章
@zh-sg
2007年學術文章
@yue
name
A randomized, double-blind com ...... tant major depressive disorder
@ast
A randomized, double-blind com ...... tant major depressive disorder
@en
A randomized, double-blind com ...... tant major depressive disorder
@nl
type
label
A randomized, double-blind com ...... tant major depressive disorder
@ast
A randomized, double-blind com ...... tant major depressive disorder
@en
A randomized, double-blind com ...... tant major depressive disorder
@nl
prefLabel
A randomized, double-blind com ...... tant major depressive disorder
@ast
A randomized, double-blind com ...... tant major depressive disorder
@en
A randomized, double-blind com ...... tant major depressive disorder
@nl
P2093
P3181
P356
P1476
A randomized, double-blind com ...... tant major depressive disorder
@en
P2093
David B Henley
Michael Case
Michael E Thase
Olawale Osuntokun
Sanjay Dubé
Sara A Corya
Susan B Watson
Todd M Sanger
P304
P3181
P356
10.4088/JCP.V68N0207
P407
P577
2007-02-01T00:00:00Z